Smith & Nephew - SN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: GBX 3,956.20
  • Forecasted Upside: 306.68%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
GBX 972.80
▼ -4.4 (-0.45%)

This chart shows the closing price for SN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Smith & Nephew Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SN

Analyst Price Target is GBX 3,956.20
▲ +306.68% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Smith & Nephew in the last 3 months. The average price target is GBX 3,956.20, with a high forecast of £145 and a low forecast of GBX 1,150. The average price target represents a 306.68% upside from the last price of GBX 972.80.

This chart shows the closing price for SN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in Smith & Nephew. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/5/2024Berenberg BankReiterated RatingBuy£145
7/16/2024Berenberg BankReiterated RatingHoldGBX 1,450
5/7/2024Royal Bank of CanadaReiterated RatingOutperformGBX 1,500
5/3/2024Jefferies Financial GroupReiterated RatingBuyGBX 1,250
5/2/2024JPMorgan Chase & Co.Boost TargetOverweightGBX 1,300 ➝ GBX 1,381
5/2/2024Berenberg BankReiterated RatingBuyGBX 1,450
4/18/2024JPMorgan Chase & Co.Reiterated RatingOverweightGBX 1,300
4/5/2024Royal Bank of CanadaReiterated RatingOutperformGBX 1,500
4/3/2024JPMorgan Chase & Co.Reiterated RatingOverweightGBX 1,300
2/9/2024BarclaysReiterated RatingEqual WeightGBX 1,150
11/30/2023BarclaysReiterated RatingEqual WeightGBX 1,150
11/30/2023Berenberg BankReiterated RatingBuyGBX 1,500
11/30/2023JPMorgan Chase & Co.Reiterated RatingOverweightGBX 1,248
11/6/2023Royal Bank of CanadaLower TargetOutperformGBX 1,600 ➝ GBX 1,500
10/2/2023BarclaysReiterated RatingUnderweightGBX 1,200
7/20/2023JPMorgan Chase & Co.Reiterated RatingNeutral
7/3/2023JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,612
6/15/2023CitigroupReiterated RatingBuy
5/16/2023Berenberg BankBoost TargetBuyGBX 1,400 ➝ GBX 1,500
4/27/2023BarclaysBoost TargetUnderweightGBX 1,100 ➝ GBX 1,200
3/14/2023CitigroupReiterated RatingBuy
3/8/2023Berenberg BankReiterated RatingBuyGBX 1,400
3/1/2023Liberum CapitalUpgradeBuyGBX 1,120 ➝ GBX 1,410
2/22/2023BarclaysLower TargetOverweightGBX 1,500 ➝ GBX 1,480
11/17/2022Berenberg BankReiterated RatingBuyGBX 1,400
11/9/2022Berenberg BankReiterated RatingBuy
11/7/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,500
11/4/2022BarclaysLower TargetOverweightGBX 1,530 ➝ GBX 1,500
10/27/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,500
10/4/2022BarclaysLower TargetOverweightGBX 1,550 ➝ GBX 1,530
9/13/2022Royal Bank of CanadaReiterated RatingSector PerformGBX 1,500
9/8/2022Berenberg BankLower TargetBuyGBX 1,800 ➝ GBX 1,400
8/4/2022JPMorgan Chase & Co.Lower TargetNeutralGBX 1,442 ➝ GBX 1,243
8/4/2022Credit Suisse GroupLower TargetOutperformGBX 1,540 ➝ GBX 1,400
8/4/2022BarclaysLower TargetOverweightGBX 1,630 ➝ GBX 1,550
7/26/2022Berenberg BankLower TargetBuyGBX 1,825 ➝ GBX 1,490
7/21/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,700
7/14/2022Berenberg BankReiterated RatingBuyGBX 1,800
7/4/2022BarclaysLower TargetOverweightGBX 1,650 ➝ GBX 1,630
7/1/2022JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,442
5/31/2022BarclaysLower TargetOverweightGBX 1,680 ➝ GBX 1,650
5/4/2022Berenberg BankLower TargetBuyGBX 1,840 ➝ GBX 1,800
5/4/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,700
4/5/2022BarclaysBoost TargetOverweightGBX 1,670 ➝ GBX 1,680
4/1/2022JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,442
3/24/2022Royal Bank of CanadaReiterated RatingOutperformGBX 1,700
3/15/2022Royal Bank of CanadaInitiated CoverageOutperformGBX 1,700
3/3/2022Berenberg BankReiterated RatingBuyGBX 1,840
2/24/2022BarclaysLower TargetOverweightGBX 1,685 ➝ GBX 1,670
2/9/2022BarclaysLower TargetEqual WeightGBX 1,700 ➝ GBX 1,685
2/8/2022JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,376
1/31/2022JPMorgan Chase & Co.Lower TargetNeutralGBX 1,379 ➝ GBX 1,376
1/13/2022JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,379
1/4/2022JPMorgan Chase & Co.Reiterated RatingNeutral
12/17/2021Berenberg BankBoost TargetBuyGBX 1,825 ➝ GBX 1,840
12/9/2021JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,379
11/10/2021BarclaysReiterated RatingOverweightGBX 1,760
11/5/2021JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,379
11/4/2021Berenberg BankLower TargetBuyGBX 1,880 ➝ GBX 1,825
11/4/2021Shore CapitalReiterated RatingHold
10/5/2021BarclaysLower TargetOverweightGBX 1,775 ➝ GBX 1,760
10/4/2021Berenberg BankLower TargetBuyGBX 2,020 ➝ GBX 1,880
9/10/2021BarclaysLower TargetOverweightGBX 1,825 ➝ GBX 1,800
8/2/2021JPMorgan Chase & Co.Boost TargetNeutralGBX 1,542 ➝ GBX 1,579
7/29/2021Shore CapitalReiterated RatingHold
7/16/2021Berenberg BankReiterated RatingBuyGBX 2,020
7/1/2021BarclaysBoost TargetOverweightGBX 1,800 ➝ GBX 1,825
6/9/2021Credit Suisse GroupUpgradeOutperformGBX 1,560 ➝ GBX 1,805
5/18/2021Shore CapitalReiterated RatingHold
4/29/2021Shore CapitalReiterated RatingHold
4/20/2021Berenberg BankReiterated RatingBuyGBX 1,985
3/2/2021Shore CapitalReiterated RatingHold
2/23/2021JPMorgan Chase & Co.Lower TargetNeutralGBX 1,563 ➝ GBX 1,423
2/12/2021Berenberg BankReiterated RatingBuyGBX 2,005
1/21/2021BarclaysLower TargetOverweightGBX 1,900 ➝ GBX 1,875
1/12/2021JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,438
11/2/2020Berenberg BankLower TargetBuyGBX 2,090 ➝ GBX 1,975
10/27/2020Shore CapitalReiterated RatingSell
7/30/2020Morgan StanleyLower TargetOverweightGBX 1,950 ➝ GBX 1,940
7/30/2020Berenberg BankLower TargetBuyGBX 2,150 ➝ GBX 2,090
7/30/2020Credit Suisse GroupLower TargetNeutralGBX 1,685 ➝ GBX 1,675
7/30/2020JPMorgan Chase & Co.Lower TargetNeutralGBX 1,633 ➝ GBX 1,553
7/29/2020Shore CapitalReiterated RatingSell
7/22/2020Credit Suisse GroupReiterated RatingNeutral
7/20/2020JPMorgan Chase & Co.Reiterated RatingNeutral
7/10/2020Berenberg BankLower TargetBuyGBX 2,165 ➝ GBX 2,150
7/9/2020Morgan StanleyLower TargetBuyGBX 2,165 ➝ GBX 2,150
7/1/2020Shore CapitalReiterated RatingSell
6/23/2020UBS GroupReiterated RatingNeutral
6/18/2020CitigroupLower TargetNeutralGBX 1,700 ➝ GBX 1,670
6/4/2020Morgan StanleyUpgradeOverweightGBX 1,990 ➝ GBX 1,950
5/15/2020Credit Suisse GroupLower TargetNeutralGBX 1,825 ➝ GBX 1,685
5/7/2020Berenberg BankBoost TargetBuyGBX 2,135 ➝ GBX 2,165
5/7/2020JPMorgan Chase & Co.Lower TargetNeutralGBX 1,658 ➝ GBX 1,633
5/6/2020Shore CapitalReiterated RatingSell
4/28/2020Jefferies Financial GroupLower TargetBuyGBX 2,160 ➝ GBX 1,800
4/17/2020Berenberg BankReiterated RatingBuy
4/14/2020CitigroupDowngradeNeutralGBX 2,250 ➝ GBX 1,700
3/31/2020UBS GroupReiterated RatingNeutral
3/31/2020JPMorgan Chase & Co.Lower TargetNeutralGBX 1,926 ➝ GBX 1,658
3/30/2020Sanford C. BernsteinDowngradeMarket Perform
3/30/2020Shore CapitalReiterated RatingSell
3/26/2020Berenberg BankLower TargetBuyGBX 2,335 ➝ GBX 2,135
2/26/2020UBS GroupBoost TargetNeutralGBX 1,800 ➝ GBX 1,860
2/25/2020Berenberg BankBoost TargetBuyGBX 2,325 ➝ GBX 2,335
2/21/2020JPMorgan Chase & Co.Boost TargetNeutralGBX 1,711 ➝ GBX 1,926
2/20/2020Shore CapitalReiterated RatingSell
2/17/2020UBS GroupReiterated RatingNeutral
2/12/2020Berenberg BankBoost TargetBuyGBX 2,185 ➝ GBX 2,325
2/5/2020JPMorgan Chase & Co.Reiterated RatingNeutral
1/24/2020Shore CapitalReiterated RatingSell
1/21/2020Jefferies Financial GroupLower TargetBuyGBX 2,200 ➝ GBX 2,160
1/15/2020The Goldman Sachs GroupLower TargetNeutralGBX 1,695 ➝ GBX 1,670
(Data available from 12/22/2019 forward)

News Sentiment Rating

1.22 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/26/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2024
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/23/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2024
  • 2 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/22/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2024

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Smith & Nephew logo
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Read More

Today's Range

Now: GBX 972.80
Low: 967.60
High: 981

50 Day Range

MA: GBX 1,011.79
Low: 917.60
High: 1,129

52 Week Range

Now: GBX 972.80

Volume

3,820,975 shs

Average Volume

343,671 shs

Market Capitalization

£8.48 billion

P/E Ratio

3,602.96

Dividend Yield

2.59%

Beta

0.62

Frequently Asked Questions

What sell-side analysts currently cover shares of Smith & Nephew?

The following sell-side analysts have issued reports on Smith & Nephew in the last year: Barclays PLC, Berenberg Bank, Jefferies Financial Group Inc., JPMorgan Chase & Co., and Royal Bank of Canada.
View the latest analyst ratings for SN.

What is the current price target for Smith & Nephew?

0 Wall Street analysts have set twelve-month price targets for Smith & Nephew in the last year. Their average twelve-month price target is GBX 3,956.20, suggesting a possible upside of 306.7%. Berenberg Bank has the highest price target set, predicting SN will reach £145 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of GBX 1,150 for Smith & Nephew in the next year.
View the latest price targets for SN.

What is the current consensus analyst rating for Smith & Nephew?

Smith & Nephew currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SN.

What other companies compete with Smith & Nephew?

Other companies that are similar to Smith & Nephew include Haleon, The Sage Group, Warehouse REIT, Anpario and Calnex Solutions. Learn More about companies similar to Smith & Nephew.

How do I contact Smith & Nephew's investor relations team?

Smith & Nephew's physical mailing address is 15 Adam Street, LONDON, WC2N 6LA, United Kingdom. The company's listed phone number is +44-20-74017646. The official website for Smith & Nephew is www.smith-nephew.com. Learn More about contacing Smith & Nephew investor relations.